Abstract Objective Prolactinomas are the most common functioning pituitary neuroendocrine tumours (PitNETs). In transgender women, gender-affirming hormone therapy (GAHT) usually combines high doses of oestrogen and anti-androgen therapy, both of which can elevate serum prolactin levels. Whether GAHT influences tumour behaviour in patients with pre-existing prolactinomas remains unclear. Design and methods Case report illustrating the clinical challenges in managing a prolactinoma in the context of GAHT initiation combined with a systematic review of all published cases and available guidelines of GAHT in the prolactinoma context. Results A 22-year-old female (46,XY; assigned male at birth) with untreated gender dysphoria and hypogonadism was diagnosed with a macroprolactinoma (39.9 mm; serum prolactin 285x upper limit of normal (ULN)). Cabergoline therapy reduced prolactin levels to 27.3xULN within one year. Pituitary apoplexy with acute visual field and acuity deterioration required emergency transsphenoidal debulking. Two months postoperatively, prolactin levels were 8.6xULN with total hypopituitarism and small irresectable remnants. Initiation of oestrogen therapy led to unexpected biochemical (128.4xULN) and radiological progression despite cabergoline reintroduction and dose escalation, necessitating oestrogen withdrawal to stabilize disease. Subsequent radiotherapy allowed safe oestrogen reintroduction. To date, 24 prolactinomas in transgender women (including this case) have been reported, most diagnosed after GAHT initiation and lacking baseline prolactin data. Current clinical guidelines provide no specific recommendations for pituitary tumours in this population. Conclusions GAHT initiation might induce rapid progression and concomitant dopamine-agonist resistance in residual macroprolactinoma. Individualized, multidisciplinary management is needed. Development of dedicated clinical guidelines is essential to combine tumour control with gender-affirming care.
Jentus et al. (Wed,) studied this question.